We are experiencing intermittent navigation issues with our website. Some of our navigation options are not appearing correctly. We are working to restore the situation quickly. Thank you for understanding.
We are experiencing intermittent navigation issues with our website. Some of our navigation options are not appearing correctly. We are working to restore the situation quickly. Thank you for understanding.
ConjuChem creates novel, next-generation medicines using unique, long-acting therapeutic peptides. Underlying all ConjuChem compounds are bioconjugation platforms called Drug Affinity Complex (DACTM) and Preformed Conjugate-Drug Affinity Complex (PC-DACTM). When applied to a given peptide, DACTM and PC-DACTM can create new drugs with similar therapeutic activities but with significantly longer durations of activity and improved safety profiles.
Your privacy
BDC uses cookies to improve your experience on its website and for advertising purposes, to offer you products or services that are relevant to you. By clicking ῝I understand῎ or by continuing to browse this site, you consent to their use.